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Pratt and Hyder’s (2016) article highlights the importance of achieving a new global health ethics that 
balances an appreciation of global interdependence against the need for ongoing protection of local 
interests. While Pratt and Hyder offer a promising framework for working towards these goals through 
the governance of global health research consortia, their framework is silent on the process of 
globalization itself—i.e. on the ways in which global networks form. This lacuna is significant because 
globalization is not a single process. Rather, globalization is a heterogeneous set of patterns occurring 
within a world that is best understood as an unstable complex system (Benatar et al. 2005). Also, 
globalisation does not, in reality, lead to uniformity, but rather to reconﬁgurations of labor and human 
resources, technological capabilities, capital and finances, information and information technology, as 
well as ideologies and epistemologies (Appadurai 1990). In the context of biomedical research, 
globalization fundamentally reconfigures the ways in which health and illness are defined, evidence is 
generated, and interventions are prioritized.  
Importantly for bioethics, the processes of globalization are largely driven by those who have the most 
social, political, scientific and/or economic capital. In the research context, this means that globalization 
affords translocal networks of researchers the opportunity to adopt or partner with institutions in 
countries with the most favorable ethical, regulatory and practical benefits that enhance their global 
competitiveness. While this no doubt facilitates research, it also allows countries that are already 
dominant in the field to drive the research agenda and financial feasibility of research consortia. It also 
allows universalistic perspectives to be imposed upon countries that lack the power to resist. In Nepal, 
for example well-meaning international research partnerships have enabled universalistic biomedical 
perspectives of psychiatric problems to supersede locally informed conceptualizations of wellbeing in 
ways that have displaced local buffers against mental illness, obscured the marginalization of vulnerable 
communities, and perpetuated structural inequalities (Harper 2014:83-102).  
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Just as powerful nation-states may drive the process and outcomes of globalization, so also may 
powerful industries, such as the pharmaceutical industry, come to dominate the globalization process. A 
case in point is the national vitamin A program in Nepal, which aimed to address vitamin A deficiency. In 
this research consortium, commercial imperatives led to sociopolitical determinants of health being 
brushed aside, and the project instead being framed in biomedical terms in ways that promoted the 
financial and ethical capital of the pharmaceutical companies involved (Harper 2014:103-122). This 
situation is not unique, with other global consortia, such as those focused on type 2 diabetes, similarly 
influencing the politics of evidence in a manner that favored individual responsibilization and 
pharmaceutical treatment while drawing attention away from prevention strategies, and discouraging 
political engagement with the social, historical and economic dimensions of disease (Mendenhall et al. 
2016; Yamada et al. 2016). In these ways, translocal health research can play into existing discriminatory 
modes of power that privilege the wealthy and sustain structural injustice. More specifically, the direct 
benefits of global health initiatives typically favor groups who may be subordinate but not so 
subordinate that they are unable to integrate into foreign models of health research. For example, living 
in a low- or middle-income country may, in theory, qualify someone to participate in a particular 
research project, but it is mostly those who are well-off and well-educated who are able to participate. If 
translocal research alliances are to have the breadth of coverage necessary to address global health, 
then their alliances need to encompass marginalized communities.  
The ways in which transnational networks are formed can not only shape their priorities, but also make 
them difficult to govern as a result of the distribution and compartmentalization of technical, financial 
and media expertise. While translocal research initiatives may have transnational reach, they do not 
have supranational power, and individual projects still take place within the framework of nation-states, 
each with their own legal and regulatory structures. Thus, while researchers participating in translocal 
networks may be more closely tied to each other than to any particular national allegiances, nation-
states still remain the arbiters of how global research consortia distribute, compartmentalize, and 
deploy their resources and activities. The ethical governance of global health research consortia must, 
therefore, take into account the sociopolitical history and cultural construction of the nation-states in 
which projects are implemented, as well as a plurality of knowledge and community values, not only 
across different nation-states, but also within them. 
Global health consortia should arguably aim to supplant these constraining national structures. For 
unless they do so, their operations are only going to be effectual with respect to their political, academic 
and social institutional capacity, the collaborative research capacity of the nation-states in which they 
are embedded, and the ability of societies to “glocalise” (adapt global practices to local conditions; see 
Robertson 1994) the standards, practices, and funding models of biomedical science. This is a serious 
limitation because systems of health governance need to not only address the actions of researchers, 
but also to have sway over the funding models that drive transnational research projects. Countries like 
Egypt and China, for example, have strict laws about the export of human biological samples, which 
impacts upon the types of international collaboration that are possible. While this may bolster local 
biomedical infrastructure for some international research projects, it may compromise the participation 
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of these countries in global research consortia where funding is tied to particular forms of research and 
to particular ideas of human tissue.   
Governance of global health research also needs to be able to conduct longitudinal monitoring of 
projects to study and analyze unintended consequences at multiple levels of complexity, and determine 
if the initiative is reproducing or reinforcing the kinds of structural violence that sustain health 
inequities. For example, to avoid the harms of epistemological imperialism, ethical governance needs to 
question the “grobalisation” (international spread of local practices; see Ritzer 2003) of scientific 
standards, methods and practices.  In current practice this means that, in order to achieve the goals of 
global health justice, research consortia need to be prepared to engage in dialogue with diverse national 
and subnational agents with plural epistemologies to determine, for example, who is able to participate 
in, and benefit from, these health research initiatives, and who is excluded. 
Unless biomedical research initiatives explicitly address and respond to the challenges raised by 
globalization, they may simply reproduce existing inequities and fail to gain the trust needed for long-
term viability (Lipworth and Kerridge 2015). This is no simple matter for, as we have argued, not only do 
ethical issues become exponentially more complex when research is globalized, but many new ethical 
issues emerge. In order to deploy the evaluation of global research consortia checklist assembled by 
Pratt and Hyder (2016), shared health governance needs to be formed by polycentric coalitions that 
have a clear process for staging dialogues and alliances between diverse forms of knowledge, dealing 
with conflicts of interest, engaging with pluralistic community values, and working towards the 
democratization of bioethics, as well as a sound ability to create distance (processes of separation) 
between global health research consortia members, sponsors, national organizations and the program 
staff so that projects are consistent with the goals of the consortia. To move to what Santos et al. 
(2007:xiv) call an “emancipatory, non-relativistic cosmopolitan ecology of knowledges”, marginalized 
communities need to have representation, leverage, and power in shared health governance, otherwise 
global research consortia will only end up sustaining global health inequities. Challenging the dominant 
structures that maintain social inequalities worldwide will require problematizing rhetorical 
conceptualizations of the global as well as re-invisaging the ecologies of knowledge that are prioritized 
in global health research governance. 
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